JOP20210216A1 - علاج السرطان - Google Patents
علاج السرطانInfo
- Publication number
- JOP20210216A1 JOP20210216A1 JOP/2021/0216A JOP20210216A JOP20210216A1 JO P20210216 A1 JOP20210216 A1 JO P20210216A1 JO P20210216 A JOP20210216 A JO P20210216A JO P20210216 A1 JOP20210216 A1 JO P20210216A1
- Authority
- JO
- Jordan
- Prior art keywords
- cancer treatment
- erdafitinib
- patients
- provides
- present
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229950004444 erdafitinib Drugs 0.000 abstract 1
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19156806 | 2019-02-12 | ||
| EP19176575 | 2019-05-24 | ||
| PCT/EP2020/053490 WO2020165181A1 (en) | 2019-02-12 | 2020-02-11 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210216A1 true JOP20210216A1 (ar) | 2023-01-30 |
Family
ID=69467563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0216A JOP20210216A1 (ar) | 2019-02-12 | 2020-02-11 | علاج السرطان |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220168298A1 (https=) |
| EP (1) | EP3923942A1 (https=) |
| JP (2) | JP2022521173A (https=) |
| KR (1) | KR20210126654A (https=) |
| CN (1) | CN113423402A (https=) |
| AU (1) | AU2020223467B2 (https=) |
| BR (1) | BR112021015686A2 (https=) |
| CA (1) | CA3126959A1 (https=) |
| IL (1) | IL285466A (https=) |
| JO (1) | JOP20210216A1 (https=) |
| MA (1) | MA54932A (https=) |
| MX (1) | MX2021009670A (https=) |
| PH (1) | PH12021551949A1 (https=) |
| SG (1) | SG11202107850VA (https=) |
| TW (1) | TWI863962B (https=) |
| WO (1) | WO2020165181A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023553533A (ja) * | 2020-12-11 | 2023-12-21 | エラスカ，インク． | 癌の処置のための併用療法 |
| CN117083283A (zh) * | 2020-12-11 | 2023-11-17 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| CN112957368A (zh) * | 2021-04-02 | 2021-06-15 | 南昌大学 | 一种司维拉姆的新用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4063516A1 (en) * | 2014-09-26 | 2022-09-28 | Janssen Pharmaceutica NV | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| TWI719960B (zh) * | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| AU2016341445B2 (en) * | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| AU2018216969B2 (en) * | 2017-02-06 | 2024-04-11 | Janssen Pharmaceutica Nv | Cancer treatment |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
-
2020
- 2020-02-11 PH PH1/2021/551949A patent/PH12021551949A1/en unknown
- 2020-02-11 WO PCT/EP2020/053490 patent/WO2020165181A1/en not_active Ceased
- 2020-02-11 KR KR1020217028671A patent/KR20210126654A/ko not_active Ceased
- 2020-02-11 CN CN202080013784.5A patent/CN113423402A/zh active Pending
- 2020-02-11 MA MA054932A patent/MA54932A/fr unknown
- 2020-02-11 BR BR112021015686-0A patent/BR112021015686A2/pt unknown
- 2020-02-11 EP EP20703477.8A patent/EP3923942A1/en active Pending
- 2020-02-11 SG SG11202107850VA patent/SG11202107850VA/en unknown
- 2020-02-11 JO JOP/2021/0216A patent/JOP20210216A1/ar unknown
- 2020-02-11 US US17/430,025 patent/US20220168298A1/en active Pending
- 2020-02-11 AU AU2020223467A patent/AU2020223467B2/en active Active
- 2020-02-11 JP JP2021547154A patent/JP2022521173A/ja not_active Withdrawn
- 2020-02-11 CA CA3126959A patent/CA3126959A1/en active Pending
- 2020-02-11 MX MX2021009670A patent/MX2021009670A/es unknown
- 2020-02-12 TW TW109104389A patent/TWI863962B/zh active
-
2021
- 2021-08-09 IL IL285466A patent/IL285466A/en unknown
-
2025
- 2025-09-29 JP JP2025162216A patent/JP2026016402A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022521173A (ja) | 2022-04-06 |
| EP3923942A1 (en) | 2021-12-22 |
| PH12021551949A1 (en) | 2022-07-18 |
| AU2020223467B2 (en) | 2025-12-04 |
| KR20210126654A (ko) | 2021-10-20 |
| CA3126959A1 (en) | 2020-08-20 |
| SG11202107850VA (en) | 2021-08-30 |
| MX2021009670A (es) | 2021-09-08 |
| CN113423402A (zh) | 2021-09-21 |
| AU2020223467A1 (en) | 2021-08-05 |
| TW202045173A (zh) | 2020-12-16 |
| JP2026016402A (ja) | 2026-02-03 |
| MA54932A (fr) | 2021-12-22 |
| TWI863962B (zh) | 2024-12-01 |
| IL285466A (en) | 2021-09-30 |
| WO2020165181A1 (en) | 2020-08-20 |
| BR112021015686A2 (pt) | 2021-10-26 |
| US20220168298A1 (en) | 2022-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| IL285847A (en) | Methods for treating map3k8 positive cancers | |
| EA201991818A1 (ru) | Лечение рака | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| JOP20190190B1 (ar) | معالجة سرطان | |
| BR112018001853A2 (pt) | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio | |
| EA201692472A1 (ru) | Соединения для лечения рака мозга | |
| MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| SG10201809411PA (en) | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab | |
| EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
| EA202191086A1 (ru) | Комбинированная терапия меланомы | |
| EA202091881A1 (ru) | Соединения для лечения боли | |
| ZA202103975B (en) | Methods of treating disease with magl inhibitors | |
| EA201890868A1 (ru) | Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей | |
| IL281439A (en) | Combined treatment for blood cancer | |
| TW201613587A (en) | Medical treatments based on anamorelin | |
| PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
| JOP20210216A1 (ar) | علاج السرطان | |
| EA202092824A1 (ru) | Комбинированная терапия | |
| IL283564A (en) | Radiation-treated fibers, methods of treating and applications for use | |
| EA202192163A1 (ru) | Лечение рака | |
| IL290213A (en) | Methods of treating multifocal cancer | |
| MX2022013883A (es) | Compuestos de metiltioninio para uso en el tratamiento de covid-19. | |
| IL286353A (en) | Combinations of iadademstat for cancer therapy |